GSK/GSK

$44.61

0.04%
-
1D1W1MYTD1YMAX

About GSK

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.

Ticker

GSK

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Emma Walmsley

Employees

70,212

Headquarters

Brentford, United Kingdom

GSK Metrics

BasicAdvanced
$93B
Market cap
16.22
P/E ratio
$2.77
EPS
0.67
Beta
-
Dividend rate
3.29%
Dividend yield
$93B
0.67465
$45.93
$33.33
3.2M
0.867
0.58
109.509
128.41
53.46%
37.213
11.37%
8.13%
34.95%
12.25%
16.222
2.387
5.304
24.178
3.29%
5.69%
-0.96%
7.59%
2.67%

What the Analysts think about GSK

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 5 analysts.
3.99% upside
High $52.50
Low $43.11
$44.61
Current price
$46.39
Average price target

GSK Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
14.2% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
£7.4B
-8.56%
Net income
£1B
198.86%
Profit margin
14.2%
227.19%

GSK Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 20.11%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.97
$1.28
$0.72
$1.09
-
Expected
$0.87
$1.14
$0.76
$0.91
$0.96
Surprise
11.72%
11.93%
-5.66%
20.11%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for GSK stock?

GSK (GSK) has a market cap of $93B as of May 22, 2024.

What is the P/E ratio for GSK stock?

The price to earnings (P/E) ratio for GSK (GSK) stock is 16.22 as of May 22, 2024.

Does GSK stock pay dividends?

No, GSK (GSK) stock does not pay dividends to its shareholders as of May 22, 2024.

When is the next GSK dividend payment date?

GSK (GSK) stock does not pay dividends to its shareholders.

What is the beta indicator for GSK?

GSK (GSK) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the GSK stock price target?

The target price for GSK (GSK) stock is $46.39, which is 4.34% above the current price of $44.46. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell GSK stock

Buy or sell GSK stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing